Dose Finding and Safety Study of Deferoxamine in Patients With Brain Hemorrhage

Model scores of the 29,894 trials active now.

Model score 19% for any early termination, 10% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 18% of the time (141 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2010-04-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: to determineironbrainhourshemorrhage
  Phrases that lowered it: the efficacyclinicalevaluatesafetyto administration
• Primary purpose: other (lowers risk) · Design
• Sponsor's past termination rate: 15.4% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Collaborators: 5 (lowers risk) · Design
• Phase: 1 (lowers risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: single group (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 24 (lowers risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Maximum age: not given (raises risk) · Who can join
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Drug's FAERS reports before start: 220 (lowers risk) · Drug's FDA history
• Drug's FAERS reports with a death: 17.3% (lowers risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 59 (lowers risk) · Drug's FDA history
• Responsible party: principal investigator (lowers risk) · Design
• Keywords listed: 3 (raises risk) · Design
• Drug's FAERS reports marked serious: 91.8% (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• High-Dose Deferoxamine in Intracerebral Hemorrhage NCT01662895 · started 2013 · scored riskier than 93% of active trials terminated
• Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial NCT02175225 · started 2014 · scored riskier than 91% of active trials completed
• Thrombolysis and Deferoxamine in Middle Cerebral Artery Occlusion NCT00777140 · started 2008 · scored riskier than 78% of active trials completed
• Iron Chelation in the Prevention of Secondary Degeneration After Stroke NCT05111821 · started 2022 · scored riskier than 65% of active trials terminated
• Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH). NCT03338998 · started 2017 · scored riskier than 97% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.